Adverse Reactions and Attitudes Toward the BNT162b2 COVID-19 Vaccine in Children 5 to 11 Years of Age in Japan

Matsumoto, Naomi; Shimizu, Junya; Yokoyama, Yuji; Tsukahara, Hirokazu; Yorifuji, Takashi

doi:10.2188/jea.je20220265

Cited by 3 publications

(1 citation statement)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We subsequently described the reported adverse reactions for each age group (6 months to under 2 years, and 2–4 years at the time of their first dose). To examine the association between previous COVID‐19 infection, co‐administration with seasonal influenza vaccination, and post‐vaccination fever, we performed Poisson regressions using robust error variance to calculate risk ratios with 95% CIs, 25 adjusting for age (continuous), sex (binary), presence of underlying medical conditions (binary), history of allergies (binary), and the number of vaccine doses (categorical; first, second, third dose), based on previous studies 26 . We also described the reasons and sources of information that influenced parents' decisions to vaccinate their child.…”

Section: Methodsmentioning

confidence: 99%

Adverse reactions in young children receiving the coronavirus disease 2019 vaccine

Matsumoto,

Shimizu,

Yokoyama

et al. 2023

Pediatrics International

Self Cite

View full text Add to dashboard Cite

BackgroundWe sought to investigate the occurrence of adverse reactions in Japanese children aged 6 months to 4 years who received the BNT162b2 coronavirus disease 2019 (COVID‐19) vaccine, to examine parental considerations, and to evaluate potential risk factors associated with post‐vaccination fever.MethodsThis cross‐sectional survey study targeted 1617 children aged 6 months to 4 years who received their primary doses of BNT162b2 from November 10, 2022, to April 30, 2023, in Okayama Prefecture. We surveyed the occurrence of local and systemic reactions within 1 week after vaccination, and described the incidence proportions of adverse reactions for 515 participants overall and by age group. The study also examined the impact of previous COVID‐19 infection and co‐administration of the seasonal influenza vaccine on post‐vaccination fever. A survey also assessed parents' reasons for vaccinating their children and the sources of information they used.ResultsAdverse reactions were infrequent (5.2%, with fever ≥37.5°C; no cases exceeded 39°C) and did not increase with vaccine doses administered. The risk of post‐vaccination fever was not statistically associated with a history of COVID‐19—the adjusted risk ratio (aRR) was 0.99, and the 95% confidence interval (CI) was 0.41–2.39—but was associated with co‐administration of the seasonal influenza vaccine (aRR 3.24, 95% CI 1.14–9.18). Parental decisions regarding vaccination were influenced by official government guidelines and primary care physicians' opinion.ConclusionThis study provides valuable insight into the safety profile of the BNT162b2 vaccine in Japanese children aged 6 months to 4 years. Further research involving larger cohorts and appropriate control groups is needed.

show abstract

Section: Methodsmentioning

confidence: 99%

Adverse reactions in young children receiving the coronavirus disease 2019 vaccine

Matsumoto,

Shimizu,

Yokoyama

et al. 2023

Pediatrics International

Self Cite

View full text Add to dashboard Cite

show abstract

Unlocking insights: Navigating COVID-19 challenges and Emulating future pandemic Resilience strategies with strengthening natural immunity

Wimalawansa

2024

Heliyon

View full text Add to dashboard Cite

Safety and antibody response of the BNT162b2 SARS-CoV-2 vaccine in children aged 5–11 years with underlying diseases: A prospective observational study

Funaki,

Yamada,

Miyake

et al. 2024

Journal of Infection and Chemotherapy

View full text Add to dashboard Cite

Adverse Reactions and Attitudes Toward the BNT162b2 COVID-19 Vaccine in Children 5 to 11 Years of Age in Japan

Abstract: This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the Version of Record.

Cited by 3 publications

References 4 publications

Adverse reactions in young children receiving the coronavirus disease 2019 vaccine

Adverse reactions in young children receiving the coronavirus disease 2019 vaccine

Unlocking insights: Navigating COVID-19 challenges and Emulating future pandemic Resilience strategies with strengthening natural immunity

Safety and antibody response of the BNT162b2 SARS-CoV-2 vaccine in children aged 5–11 years with underlying diseases: A prospective observational study

Contact Info

Product

Resources

About